公开(公告)号：KR1020060135280A

公开(公告)日：2006-12-29

申请号：KR1020050055143

申请日：2005-06-24

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  이은희 ,  윤희정 ,  고창보

IPC: C12N15/867

Abstract: Novel recombinant vectors are provided to be used for expressing triggering receptor expressed on myeloid cells 2b(TREM-2) which is expressed at the activity of natural killer cell and the differentiation process and plays important role on innate immunity. The recombinant vector pcDNA3.1-TREM-2 expresses TREM-2 involved with innate immunity. The recombinant vector pLXSN-TREM-2 expresses TREM-2 involved with innate immunity.

Abstract translation: 提供新的重组载体用于表达在骨髓细胞2b（TREM-2）上表达的触发受体，其以天然杀伤细胞的活性和分化过程表达，并对先天免疫起重要作用。 重组载体pcDNA3.1-TREM-2表达涉及先天免疫的TREM-2。 重组载体pLXSN-TREM-2表达涉及先天免疫的TREM-2。

公开(公告)号：KR1020090090946A

公开(公告)日：2009-08-26

申请号：KR1020080016523

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  김동헌 ,  이은희 ,  최하림 ,  이화연

IPC: A61K39/395 ,  A61K38/00 ,  A61P35/00

CPC classification number: A61K39/39566 ,  A61K38/00 ,  Y10S514/885

Abstract: A composition for preventing and treating cervical cancer, which comprises lymphotoxin alpha/beta complex (LTalpha/beta) or lymphotoxin beta receptor (LTbeta-R) binding agent is provided to use an agent for preventing or treating cervical cancer by inducing the mucosa immune response. A composition for preventing and treating cervical cancer comprises limphotoxin alpha/beta complex or limphotoxin beta receptor binding agent as an active ingredient. The lymphotoxin alpha/beta complex is a surface lymphotoxin alpha/beta complex or recombinant soluble lymphotoxin alpha/beta complex. The lymphotoxin beta receptor is an antibody to lymphotoxin beta receptor. The antigen is polyclonal antibody or monoclonal antibody.

Abstract translation: 提供了一种用于预防和治疗宫颈癌的组合物，其包括淋巴毒素α/β复合物（LTα/β）或淋巴毒素β受体（LTbeta-R）结合剂，用于通过诱导粘膜免疫应答来预防或治疗宫颈癌 。 用于预防和治疗宫颈癌的组合物包含角光素α/β复合物或角叉松素β受体结合剂作为活性成分。 淋巴毒素α/β复合物是表面淋巴毒素α/β复合物或重组可溶性淋巴毒素α/β复合物。 淋巴毒素β受体是淋巴毒素β受体的抗体。 抗原是多克隆抗体或单克隆抗体。

公开(公告)号：KR100650384B1

公开(公告)日：2006-11-30

申请号：KR1020060070390

申请日：2006-07-26

Applicant: 전남대학교산학협력단 ,  주식회사 굿셀라이프

Inventor： 강형식 ,  김은미 ,  김상현 ,  윤지연 ,  고창보 ,  허영진 ,  심우영 ,  허성범 ,  이은희 ,  윤희정

IPC: C07K2/00

Abstract: A method for differentiating precursor natural killer cell into mature natural killer cell is provided to obtain large amount of the mature natural killer cell by treating the precursor natural killer cell with Axl receptor tyrosine kinase. The composition for inducing differentiation of precursor natural killer cell into mature natural killer cell is characterized in that it includes at least one ligand selected from the group consisting of antibody of Axl receptor tyrosine kinase(Axl), gamma-carboxylated growth-arrest specific gene6(Gas6) protein and protein S as a ligand of the Axl. The method comprises the steps of: (a) treating hematopoietic stem cell with interleukin-7, stem cell factor and Flt3 ligand to be differentiated into precursor natural killer cell; and (b) treating the precursor natural killer cell with at least one selected from the group consisting of antibody of Axl receptor tyrosine kinase(Axl), gamma-carboxylated growth-arrest specific gene6(Gas6) protein and protein S.

Abstract translation: 通过用Axl受体酪氨酸激酶处理前体天然杀伤细胞来提供将前体天然杀伤细胞分化为成熟天然杀伤细胞以获得大量成熟天然杀伤细胞的方法。 用于诱导前体天然杀伤细胞分化为成熟自然杀伤细胞的组合物的特征在于其包含至少一种选自Axl受体酪氨酸激酶抗体（Axl），γ-羧化生长抑制特异性基因6（ Gas6）蛋白和蛋白S作为Axl的配体。 该方法包括以下步骤：（a）用白细胞介素-7，干细胞因子和Flt3配体处理造血干细胞以分化成前体天然杀伤细胞; 和（b）用选自Axl受体酪氨酸激酶抗体（Axl），γ-羧化生长抑制特异性基因6（Gas6）蛋白质和蛋白质S中的至少一种处理前体天然杀伤细胞。